Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

David M CharytanScott D SolomonPeter IvanovichGiuseppe RemuzziMark E CooperJanet B McGillHans-Henrik ParvingPatrick ParfreyAjay K SinghEmmanuel A BurdmannAndrew S LeveyKai-Uwe EckardtJohn Joseph Valentine McMurrayLarry A WeinrauchJiankang LiuBrian ClaggettEldrin F LewisMarc A Pfeffer

Published in: Diabetes, obesity & metabolism (2019)

Metformin may be safer for use in CKD than previously considered and may lower the risk of death and cardiovascular events in individuals with stage 3 CKD.

Keyphrases

cardiovascular events
chronic kidney disease
end stage renal disease
coronary artery disease
cardiovascular disease